AQR Capital Management
CRNX icon

AQR Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

AQR Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,798
Closed -$399K – 3161
2024
Q4 		$399K Buy
7,798
+230
+3% +$12.9K ﹤0.01% 2363
2024
Q3 		$387K Buy
7,568
+442
+6% +$22.8K ﹤0.01% 2282
2024
Q2 		$319K Buy
7,126
+227
+3% +$10.5K ﹤0.01% 2241
2024
Q1 		$323K Buy
6,899
+213
+3% +$8.33K ﹤0.01% 2105
2023
Q4 		$238K Buy
+6,686
New +$205K ﹤0.01% 2150
2022
Q3 		– Sell
-10,138
Closed -$189K – 2221
2022
Q2 		$189K Sell
10,138
-16,268
-62% -$325K ﹤0.01% 2003
2022
Q1 		$580K Buy
26,406
+1,742
+7% +$35.3K ﹤0.01% 1763
2021
Q4 		$701K Buy
+24,664
New +$608K ﹤0.01% 1711

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management's CRNX Position: Q1 2025 in Review

AQR Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 7,798 shares — an estimated $399K sold.

AQR Capital Management first reported a position in CRNX in Q4 2021 and held it in 8 quarters. The position peaked at $701K in Q4 2021. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • AQR Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • AQR Capital Management sold 7,798 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $399K.
  • AQR Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • AQR Capital Management's Crinetics Pharmaceuticals position peaked at $701K in Q4 2021.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on AQR Capital Management's 13F filing for Q1 2025, filed 15 May 2025.